Klin Farmakol Farm. 2005;19(4):216-220

hormonal treatment OF Early breast cancer

Jindřich Fínek1, Luboš Holubec jr2, Lucie Elgrová2
1 Chirurgická klinika FN Plzeň
2 Onkologické a radioterapeutické oddělení FN, Plzeň

Hormonal therapy is a potent breast cancer treatment in both neoadjuvant and adjuvant form as well as in the treatment of advanced disease.

Keywords: Key words: breast cancer, hormonal treatment, aromatase inhibitors.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fínek J, Holubec L, Elgrová L. hormonal treatment OF Early breast cancer. Klin Farmakol Farm. 2005;19(4):216-220.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Coombes RCH, Hall E, Gibbon LJ. Exemestane versus tamoxifen after initial tamoxifen therapy for breast cancer. N Engl J Med 2004; 350: 1081-1092. Go to original source... Go to PubMed...
    2. Early Brest Cancer Trialist´s Collaboration Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467. Go to original source...
    3. Fischer B, Digram J, Bryant J, et al. Five versus more then five years of tamoxifen therapy for breast cancer patiens with negative lymph nodes and estrogen positive tumors. J Natl Cancer Inst 1996; 88: 1529-1542. Go to original source... Go to PubMed...
    4. Hamilton A, Piccart M. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in second line hormonal treatment of advanced breast cancer. Ann Oncol 1999; 10: 377-384. Go to original source... Go to PubMed...
    5. Paridaens R, Dirix L, Lohrich C, et al. Mature results of randomized phase II multicenter study of exemestane versus tamoxifen in first line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003; 14: 1391-1398. Go to original source... Go to PubMed...
    6. Baum M, Buzdar AU, Cuzick J, et al. Anastrozol alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised. Lancet 2002; 359: 2131-2139. Go to original source... Go to PubMed...
    7. Boccardo F, Rubagotti A, Amoroso D, et al. Anastrozol appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2003; Suppl 1: 56, abstrakt.
    8. Atalay G, Dirix L, Biganzoli L, et al. The effect of exemestane on serum profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, randomised phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen postmenopausal patiens. Ann Oncol 2004; 15: 211-217. Go to original source... Go to PubMed...
    9. Bertelli G, et al. Sequential use of aromatase inactivators and inhibitors in advanced breast cancer. ASCO 2002, Abstract No 238.
    10. Goldhirsch A, Glick JH, Gerber RD, et al. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 2005; 16: 1569-1583. Go to original source... Go to PubMed...
    11. Schwarz MD, Kaufman E, Peshkin BN, et al. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA 1/BRCA2 mutation testing. J Clin Oncol 2003; 21: 4034-4041. Go to original source... Go to PubMed...
    12. Gerber J, Octit K. Hereditary cancer predisposition syndromes. J Clin Oncol 2005; 23: 276-292. Go to original source... Go to PubMed...
    13. Minn AJ, Kang Y, Serganova I, et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005; 115: 44-55. Go to original source... Go to PubMed...
    14. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistence: increased estrogen receptor-HER2/neu Gross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004; 96: 926-935. Go to original source... Go to PubMed...
    15. Lipton A, Ali SM, Leitzel K, et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 2203; 21: 1967-1972. Go to original source... Go to PubMed...
    16. Hayes D. Prognostic and predictive factors revisited. Brest 2005; 14 (Suppl): S6. Go to original source... Go to PubMed...
    17. Baselga J, Gianni L, Geyer C, et al. Future options with trastuzumab for primary systemic and adjuvant therapy. Semin Oncol 2004; 31: 51-57. Go to original source... Go to PubMed...
    18. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62. Go to original source... Go to PubMed...
    19. International Breast Cancer Study Group (IBCSG), on behalf of the Breast International Group (BIG). Letrozole vs.tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. BIG 1-98.: A prospective randomised double-blind phase III. study. The Primary Therapy of Early Breast Cancer 9th International Conference in St Gallen, Switzerland, 26 January 2005. Also available as: Thurlimann BJ, Keshaviah A, Mouridsen H, et al. BIG 1-98: Randomized double-blind phase III study to evaluace letrozole (L) vs. Tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer (Abstrakt). J Clin Oncol (Annual Meeting Proceedings) 2003; 23: 511.
    20. Coombes RC, Hall E, Gibbon LJ, et al. A randomised trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092. Go to original source... Go to PubMed...
    21. Jakesz R, Kaufmann M, Gnant M, et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 2004; 88: 7. Go to original source...
    22. Winer EP, Hudis C, Burstein HJ; et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptorpositive breast cancer: status report 2004. J Clin Oncol 2005; 23: 619-629. Go to original source... Go to PubMed...
    23. Colleoni M, Gerber S, Snyder R, et al. Randomized comparison of adjuvant tamoxifen (Tam) versus no hormonal treatment for premenopasal women with node-positive (N+), early stage breast cancer: First results of International Breast Cancer Study Group Trial 13-93. J Clin Oncol 2004; 22: 532 (Abstr). Go to original source...
    24. Boccardo F, Rubagotti A, Amoroso D, et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patiens: results of an Italian cooperative study. J Clin Oncol 2001; 19: 4209-4215. Go to original source... Go to PubMed...
    25. Klener P. Klinická onkologie, ISBN80-7262-151-3, Galén 2002.
    26. Howell A, Robertson JFR, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne CK. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. Journal of Clinical Oncology 2004; 22 (9): 1605-1613. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.